Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study.
Sandy Van HemelryckErika Van LanduytVeerle HufkensSimon VanveggelPublished in: Antiviral therapy (2024)
ClinicalTrials.gov Identifier: NCT04006704.